Combination of | |
---|---|
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
Clinical data | |
Trade names | Cimduo, Temixys |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618039 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][3] It contains lamivudine and tenofovir disoproxil.[1] It is taken by mouth.[1]
Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]